share_log

We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely

We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely

我们希望安妮布洛制药公司(纳斯达克代码:ANEB)将明智地使用现金
Simply Wall St ·  2022/06/28 04:50

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

我们很容易理解为什么投资者会被不盈利的公司所吸引。例如,虽然亚马逊上市后多年亏损,但如果你从1999年开始买入并持有股票,你就会发大财。但是,尽管成功是众所周知的,但投资者不应忽视许多没有盈利的公司,这些公司只是烧掉了所有的现金,然后倒闭。

Given this risk, we thought we'd take a look at whether Anebulo Pharmaceuticals (NASDAQ:ANEB) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

考虑到这种风险,我们认为我们应该看看AneBulo制药公司纳斯达克:ANEB)股东应该担心它的现金消耗。在这份报告中,我们将考虑该公司的年度自由现金流为负,此后将其称为“现金消耗”。第一步是将它的现金消耗与其现金储备进行比较,给我们提供它的“现金跑道”。

View our latest analysis for Anebulo Pharmaceuticals

查看我们对AneBulo制药公司的最新分析

How Long Is Anebulo Pharmaceuticals' Cash Runway?

AneBulo制药的现金跑道有多长?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In March 2022, Anebulo Pharmaceuticals had US$17m in cash, and was debt-free. Looking at the last year, the company burnt through US$6.9m. Therefore, from March 2022 it had 2.4 years of cash runway. That's decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.

现金跑道的定义是,如果一家公司继续以目前的现金消耗速度支出,它需要多长时间才能耗尽资金。2022年3月,AneBulo PharmPharmticals拥有1700万美元现金,而且没有债务。就去年而言,该公司烧掉了690万美元。因此,从2022年3月开始,它有了2.4年的现金跑道。这很不错,给了公司几年的时间来发展业务。你可以在下图中看到它的现金余额是如何随着时间的推移而变化的。

NasdaqCM:ANEB Debt to Equity History June 27th 2022
纳斯达克CM:ANEB债转股历史2022年6月27日

How Is Anebulo Pharmaceuticals' Cash Burn Changing Over Time?

AneBulo制药公司的现金消耗是如何随着时间的推移而变化的?

Anebulo Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. During the last twelve months, its cash burn actually ramped up 79%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

AneBulo PharmPharmticals去年没有记录任何收入,这表明它是一家仍在发展业务的早期公司。尽管如此,我们仍然可以检查其烧钱轨迹,作为我们评估其烧钱情况的一部分。在过去的12个月里,它的现金消耗实际上增加了79%。通常情况下,现金消耗的增加只是意味着一家公司正在加快其业务发展,但人们应该始终记住,这会导致现金跑道缩小。然而,显然,关键因素是该公司是否会在未来实现业务增长。因此,你可能想看看该公司在未来几年的预期增长速度。

Can Anebulo Pharmaceuticals Raise More Cash Easily?

AneBulo制药能轻松筹集更多现金吗?

Given its cash burn trajectory, Anebulo Pharmaceuticals shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

鉴于其烧钱的轨迹,AneBulo PharmPharmticals的股东可能希望考虑一下,尽管它有坚实的现金跑道,但它筹集更多现金的难度有多大。发行新股或承担债务是上市公司为其业务筹集更多资金的最常见方式。通常情况下,企业会自行发售新股,以筹集现金并推动增长。我们可以将一家公司的现金消耗与其市值进行比较,以了解一家公司需要发行多少新股才能为一年的运营提供资金。

Anebulo Pharmaceuticals' cash burn of US$6.9m is about 6.0% of its US$116m market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

AneBulo PharmPharmticals 690万美元的现金消耗约占其1.16亿美元市值的6.0%。这是一个很低的比例,所以我们认为该公司将能够筹集更多的现金来支持增长,只需一点点稀释,甚至只是借一些钱。

So, Should We Worry About Anebulo Pharmaceuticals' Cash Burn?

那么,我们应该担心AneBulo制药公司的烧钱吗?

As you can probably tell by now, we're not too worried about Anebulo Pharmaceuticals' cash burn. In particular, we think its cash burn relative to its market cap stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. On another note, we conducted an in-depth investigation of the company, and identified 4 warning signs for Anebulo Pharmaceuticals (1 is a bit concerning!) that you should be aware of before investing here.

正如你现在可能已经知道的那样,我们并不太担心AneBulo制药公司的现金消耗。特别是,我们认为它的现金消耗相对于其市值来说是突出的,证明该公司很好地控制了支出。虽然它不断增加的现金消耗并不是很好,但本文提到的其他因素足以弥补这一指标的疲软。考虑到本文讨论的所有因素,我们并不过分担心公司的现金消耗,尽管我们确实认为股东应该密切关注公司的发展。另一方面,我们对该公司进行了深入调查,并确定了AneBulo制药公司的4个警告标志(1有点令人担忧!)在这里投资之前你应该意识到这一点。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

当然了,如果你把目光投向别处,你可能会发现这是一笔很棒的投资。所以让我们来看看这个免费内部人士正在买入的公司名单,以及这份名单中的成长股(根据分析师预测)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发